Danish drugmaker Lundbeck is set to buy Bothell, Wash.-based Alder Biopharmaceuticals in a deal that could be worth up to $1.95 billion, sending Alder’s stock rocketing up 83 percent on… Read More
OceanGate, the maker of deep-sea submersibles, hired Robert Shuman as chief operating officer. Shuman previously held senior business roles at satellite company Kymeta, online course provider Apex Learning and software… Read More
Alder BioPharmaceuticals has raised $170 million in a stock offering and is ramping up operations after filing an FDA application for eptinezumab, a therapy for patients with chronic migraines. Alder… Read More
— Jill Keto signed on to be chief marketing officer at Easy Metrics, a supply chain operations startup that helps companies manage labor costs. Keto came from Apptio, where she… Read More
Carlos Campoy is the new CFO at Alder BioPharmaceuticals. The Bothell, Wash.-based drug company is developing eptinezumab, an antibody-based migraine treatment that’s currently undergoing a pivotal phase 3 trial. Campoy… Read More
In one of two recent Microsoft-to-Amazon moves, Brian Schultz, who has worked on-and-off at Microsoft since 1999, is now working on Amazon Web Services. According to his LinkedIn profile, Schultz is… Read More
Microsoft has appointed longtime legal executive Dev Stahlkopf as its general counsel after leaving the position vacant for two years. The new general counsel role was created by Brad Smith,… Read More
News Brief: Randall Schatzman, the CEO and president of Bothell, Wash., company Alder BioPharmaceuticals, is stepping down from his role as CEO and president and will also vacate his seat… Read More
Alder BioPharmaceuticals is looking to raise approximately $150 million by selling off stock in order to continue work on a migraine prevention treatment called eptinezumab, according to a Securities and Exchange… Read More
Shares of Alder BioPharmaceuticals continue to fall after the company received notice from partner Bristol-Myers Squibb Company after the giant drug company determined that Alder’s experimental rheumatoid arthritis drug Clazakizumab “did not warrant… Read More
Alder BioPharmaceuticals had a fairly ho-hum first day on Wall Street today. The Bothell-based biotech company’s stock closed at $10.03 a share today, up three cents from its IPO price of… Read More